FDA Approves NEUPOGEN — Amgen, Inc

Amgen, Inc.'s flagship product NEUPOGEN (filgrastim) received FDA approval (BLA103353) in 1991, pioneering the use of filgrastim to stimulate white blood cell production and significantly improving outcomes for patients undergoing chemotherapy-induced neutropenia. This successful launch established filgrastim as a critical market staple, creating a persistent revenue stream and validating the biotech sector's shift toward biologics as a powerful therapeutic alternative.